|
|
||||||||
Clinical Chemistry, Vol 22, 98-101, Copyright © 1976 by American Association for Clinical Chemistry
BW Steele, DF Koehler, MM Azar, TP Blaszkowski, K Kuba and ME Dempsey
An enzymatic method for cholesterol in serum [Clin. Chem. 20, 470 (1974)] was initially found to be unsatisfactory for measuring cholesterol in high-density-lipoprotein fractions prepared by precipitation with Mn2+. A fine precipitate formed in the cuvette and cholesterol values were falsely increased. We describe a simple, convenient method for circumventing these problems. An ethylenediaminetetraacetate solution is used to reconstitute the enzymatic reagent. Cholesterol values by this procedure correlated with those obtained by the Lipid Research Clinic's procedure for the same lipoprotein fraction preparations (regression slope, .998; Y-intercept, 8.9 mg/liter; correlation coefficient, .984; standard error of the estimate, 16.8 mg/liter). Precision of the assay, including the precipitation step, was calculated. The SDwithin day was 9.7 mg/liter and SDoverall was 23.7 mg/liter. Results for total cholesterol with the modified reagent were linearly related to concentrations exceeding 4 g/liter, thereby permitting determination of high-density-lipoproteins and total cholesterol in a single run.
The following articles in journals at HighWire Press have cited this article:
![]() |
R. Rej Clinical Chemistry through Clinical Chemistry: A Journal Timeline Clin. Chem., December 1, 2004; 50(12): 2415 - 2458. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. R Hiatt, E. Klepack, M. Nehler, J. G Regensteiner, J. Blue, J. Imus, and M. H Criqui The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease Vascular Medicine, November 1, 2004; 9(4): 271 - 277. [Abstract] [PDF] |
||||
![]() |
H. Schrott, A. G. Fereshetian, R. H. Knopp, H. Bays, P. H. Jones, T. W. Littlejohn, R. McLain, and D. M. Black A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 119 - 123. [Abstract] [PDF] |
||||
![]() |
S. N. Pimstone, S. E. Gagne, C. Gagne, P. J. Lupien, D. Gaudet, R. R. Williams, M. Kotze, P. W. A. Reymer, J. C. Defesche, J. J. P. Kastelein, et al. Mutations in the Gene for Lipoprotein Lipase : A Cause for Low HDL Cholesterol Levels in Individuals Heterozygous for Familial Hypercholesterolemia Arterioscler. Thromb. Vasc. Biol., October 1, 1995; 15(10): 1704 - 1712. [Abstract] [Full Text] |
||||
![]() |
J. W. Nawrocki, S. R. Weiss, M. H. Davidson, D. L. Sprecher, S. L. Schwartz, P.-J. Lupien, P. H. Jones, H. E. Haber, and D. M. Black Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor Arterioscler. Thromb. Vasc. Biol., May 1, 1995; 15(5): 678 - 682. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |